Keywords: Oxford BioMedica, Emergent BioSolutions, Hi-8 PrimeBoost vaccine technology, EBS, OXB.L, Tuberculosis
Oxford BioMedica licences Hi-8 PrimeBoost vaccines technology to Emergent BioSolutions in $20 million accord
Article | 19 August 2010
UK-based gene therapy firm Oxford BioMedica has signed a licensing deal with Emergent Product Development Germany GmbH, a wholly-owned subsidiary ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
